▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3191 by analyst upside · 2026-11-13
KOD
Kodiak Sciences Inc.
Healthcare · Market Cap $7B · P/E 0x
ANALYST PRICE TARGET
+12.4%
implied upside to consensus target
Current Price $108.25
Consensus Target $121.67
Bull Target $145.0
Bear Target $103.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
1
Sell
0
52-Week Low $18.05
52-Week High $112.31
YTD Return +316.0%
FUNDAMENTALS
Market Cap $7B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-4.19
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $18.05
52-Week High $112.31
Current Price $108.25
Bear Target $103.0
Bull Target $145.0
● Now $108.25 ● Target $121.67
TRADING DATA
Avg Volume 1.8M
YTD Return +316.0%
Analyst Count 6
Consensus Buy
Upside to Target +12.4%
Last Updated 2026-11-13

ANALYST SUMMARY

Kodiak Sciences Inc. (KOD) is currently trading at $108.25 with a Wall Street consensus price target of $121.67, implying potential upside of 12.4% over the next 12 months. 6 analysts currently cover KOD, with a consensus rating of Buy - 83% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $145.0, while the most cautious has a target of $103.0.

KOD operates in the Healthcare sector with a market capitalisation of $7B. The stock is up 316.0% year-to-date and is currently trading near the upper end of its 52-week range of $18.05 – $112.31.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for KOD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. - Reiterated
Buy → Buy 2026-10-12 31% win rate (48 calls)
LifeSci Capital - Reiterated
Outperform → Outperform 2026-09-28 Building track record
UBS - Reiterated
Buy → Buy 2026-09-28 33% win rate (6 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-09-28 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-09-17 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-08-17 31% win rate (48 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-08-03 43% win rate (7 calls)
Chardan Capital ↑ Upgrade
Neutral → Buy 2026-05-11 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
15/30
Consensus clarity
22/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →